Trading Signals: CBAY Stock Price Prediction and Forecast (Mon. Jan. 27, 2014 - Mon. Mar. 22, 2021)(CymaBay Therapeutics Inc.)
| CBAY latest price $5.7200 (-0.61%) ($5.7200 - $5.7200) on Thu. Jan. 21, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.98% (three month average) | RSI | 48 | Latest Price | $5.7200(-0.61%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | CBAY declines -1.2% a day on average for past five trading days. | Weekly Trend | CBAY advances 0.3% a week on average for past two weeks. | Market Behavior | Rotation from value to growth for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support CBAY advance at 0% a week (0% probability) XLK(73%) XOP(48%) EDOC(43%) ACES(40%) IBUY(40%) | Factors Impacting CBAY price | CBAY will decline at least -1.49% in a week (0% probabilities). XRT(-13%) XME(22%) XLV(9%) XLRE(-1%) GLD(-25%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.49% (StdDev 2.98%) | Hourly BBV | -0.7 () | Intraday Trend | 0% | | | |
|
Resistance Level | $6.09 | 5 Day Moving Average | $5.93(-3.54%) | 10 Day Moving Average | $6.11(-6.38%) | 20 Day Moving Average | $6.09(-6.08%) | To recent high | -36.7% | To recent low | 1.1% | Market Cap | $394m | | | | CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA. |